ZK824859

ZK824859 Suppliers list
Company Name: TargetMol Chemicals Inc.  
Tel: +1-781-999-5354; +1-00000000000
Email: marketing@targetmol.com
Company Name: Energy Chemical  
Tel: 021-58432009 400-005-6266
Email: marketing@energy-chemical.com
Company Name: TargetMol Chemicals Inc.  
Tel: 4008200310 15002144251
Email: marketing@tsbiochem.com
Company Name: Anhui JYHX CO., LTD.  
Tel: 055167162561 13295518198
Email: wangyanan@ahjyhx.com
Company Name: Aikon International Limited  
Tel: 025-58859352 18651614124
Email: 2881516338@qq.com

ZK824859 manufacturers

  • ZK824859
  • ZK824859 pictures
  • $2370.00
  • 2026-07-27
  • CAS:2271122-53-1
  • Purity:
  • Supply Ability: 10g
  • ZK824859
  • ZK824859 pictures
  • $2370.00
  • 2026-07-27
  • CAS:2271122-53-1
  • Purity:
  • Supply Ability: 10g
  • ZK824859
  • ZK824859 pictures
  • $1820.00
  • 2025-08-22
  • CAS:2271122-53-1
  • Purity:
  • Supply Ability: 10g
ZK824859 Basic information
Product Name:ZK824859
Synonyms:(R)-2-((6-((3'-(Aminomethyl)-5-methyl-[1,1'-biphenyl]-3-yl)oxy)-3,5-difluoropyridin-2-yl)oxy)butanoic acid;ZK824859,ZK-824859;Butanoic acid, 2-[[6-[[3'-(aminomethyl)-5-methyl[1,1'-biphenyl]-3-yl]oxy]-3,5-difluoro-2-pyridinyl]oxy]-, (2R)-;(2R)-2-[[6-[[3′-(Aminomethyl)-5-methyl[1,1′-biphenyl]-3-yl]oxy]-3,5-difluoro-2-pyridinyl]oxy]butanoic acid
CAS:2271122-53-1
MF:C23H22F2N2O4
MW:428.43
EINECS:
Product Categories:
Mol File:2271122-53-1.mol
ZK824859 Structure
ZK824859 Chemical Properties
Boiling point 542.7±50.0 °C(Predicted)
density 1.291±0.06 g/cm3(Predicted)
storage temp. Store at -20°C
solubility Soluble in DMSO
pka2.62±0.10(Predicted)
Safety Information
MSDS Information
ZK824859 Usage And Synthesis
UsesZK824859 is an oral available and selective urokinase plasminogen activator (uPA) inhibitor with IC50s of 79nM, 1580nM and 1330nM for human uPA, tPA, and plasmin, respectively[1].
in vivo

ZK824859 (50, 25 and 10mg/kg; b.i.d.; 25 days) is used in a chronic mouse EAE model. ZK 824859 completely prevents the development of disease. However, two lower doses (25 and 10mg/kg) have no effect on clinical scores[1].

Animal Model:Female SJL mice with chronic mouse EAE model[1]
Dosage:50, 25 and 10mg/kg
Administration:B.i.d.; 25 days
Result:Prevented the development of disease at 50mg/kg completely. However, 25 and 10mg/kg had no effect on clinical scores.
References[1] Islam I, et al. Discovery of selective urokinase plasminogen activator (uPA) inhibitors as a potential treatment for multiple sclerosis. Bioorg Med Chem Lett. 2018 Nov 1;28(20):3372-3375. DOI:10.1016/j.bmcl.2018.09.001
ZK824859 Preparation Products And Raw materials
Tag:ZK824859(2271122-53-1) Related Product Information
(+)-ZK 216348 ZK824859 ZK 158252 ZK164015 ZK756326(dihydrochloride) ZK 93426 hydrochloride ZK 159222 ZK 756326 ZK118182 isopropyl ester ZK-90055 (hydrochloride) ZK 110841 ZK 112993 FUDAEUIGIJZUAY-UMIRZPQISA-N ZK-261991